Kyverna Therapeutics, Inc. KYTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s operating income?
- Kyverna Therapeutics, Inc. (KYTX) reported operating income of -$41.37M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s operating income changed year-over-year?
- Kyverna Therapeutics, Inc.'s operating income increased by 12.7% year-over-year, from -$47.41M to -$41.37M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s operating income?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s operating income has grown at a 65.0% compound annual growth rate (CAGR), from -$62.41M to -$169.83M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.